Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Conservative management is now the most common choice for men with low-risk prostate cancer.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
Darolutamide delays metastasis and reduces the risk of death in men with high-risk prostate cancer.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
These men lived for a median of 30 months compared to 26 months for white men.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.